Literature DB >> 29469030

The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis.

Anne Bellemain-Appaix1, Céline Bégué, Deepak L Bhatt, Kenneth Ducci, Robert A Harrington, Matthew Roe, Stephen D Wiviott, Michel Cucherat, Johanne Silvain, Jean-Philippe Collet, François Bernasconi, Gilles Montalescot.   

Abstract

AIMS: The aim of this meta-analysis was to compare the benefit of "early" vs. "delayed" P2Y12 inhibition in patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). METHODS AND
RESULTS: We conducted a meta-analysis including seven randomised controlled trials (RCTs) which compared early vs. delayed P2Y12inhibition in STEMI patients scheduled for PCI, providing data on major adverse cardiac events (MACE), all-cause death, and major bleeding. The primary endpoint was MACE. Secondary endpoints included stent thrombosis and the use of GP IIb/IIIa inhibitors (GPI). All endpoints were analysed at the shortest follow-up available. A total of 9,648 patients were included ("early"=4,792, "delayed"=4,856). "Early" P2Y12 inhibition was associated with a significant reduction in MACE rate (OR 0.73, 95% CI: 0.61-0.88, p=0.0008), myocardial infarction (OR 0.71, 95% CI: 0.57-0.90, p=0.004), bail-out GPI use (OR 0.87, 95% CI: 0.75-1.00, p=0.04) and improved coronary reperfusion before PCI (OR for Thrombolysis In Myocardial Infarction [TIMI] flow grade 2-3=1.12, 95% CI: 1.00-1.26, p=0.04). Major bleeding was not increased (OR 0.87, 95% CI: 0.62-1.21, p=0.41).
CONCLUSIONS: A strategy of early effective P2Y12 inhibition in PCI of STEMI appears to improve coronary reperfusion before PCI, and reduce MACE, MI and bail-out GPI use without increase of major bleeding.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29469030     DOI: 10.4244/EIJ-D-17-00852

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  8 in total

Review 1.  Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach.

Authors:  Benoit Lattuca; Mathieu Kerneis; Michel Zeitouni; Guillaume Cayla; Paul Guedeney; Jean-Philippe Collet; Gilles Montalescot; Johanne Silvain
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

2.  Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.

Authors:  Juan F Iglesias; Marco Valgimigli; Federico Carbone; Nathalie Lauriers; Pier-Giorgio Masci; Sophie Degrauwe
Journal:  Cardiol J       Date:  2022-06-28       Impact factor: 3.487

3.  Mind the Gap: Platelet Inhibition in Low-Risk Acute Coronary Syndrome Undergoing Percutaneous Revascularization.

Authors:  Ravi K Sharma; Duane S Pinto
Journal:  J Am Heart Assoc       Date:  2019-11-26       Impact factor: 5.501

4.  Indirect Transfer to Catheterization Laboratory for ST Elevation Myocardial Infarction Is Associated With Mortality Independent of System Delays: Insights From the France-PCI Registry.

Authors:  Farzin Beygui; Vincent Roule; Fabrice Ivanes; Thierry Dechery; Olivier Bizeau; Laurent Roussel; Philippe Dequenne; Marc-Antoine Arnould; Nicolas Combaret; Jean Philippe Collet; Philippe Commeau; Guillaume Cayla; Gilles Montalescot; Hakim Benamer; Pascal Motreff; Denis Angoulvant; Pierre Marcollet; Stephan Chassaing; Katrien Blanchart; René Koning; Grégoire Rangé
Journal:  Front Cardiovasc Med       Date:  2022-03-11

5.  Effect of prehospital treatment in STEMI patients undergoing primary PCI.

Authors:  Enrico Fabris; Sara Menzio; Caterina Gregorio; Andrea Pezzato; Davide Stolfo; Aneta Aleksova; Giancarlo Vitrella; Serena Rakar; Andrea Perkan; Arnoud Wj Van't Hof; Gianfranco Sinagra
Journal:  Catheter Cardiovasc Interv       Date:  2022-03-15       Impact factor: 2.585

Review 6.  Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead.

Authors:  Enrico Fabris; Serge Korjian; Barry S Coller; Jurrien M Ten Berg; Christopher B Granger; C Michael Gibson; Arnoud W J van 't Hof
Journal:  Thromb Haemost       Date:  2021-04-30       Impact factor: 6.681

7.  Optimal Timing of Invasive Coronary Angiography following NSTEMI.

Authors:  Thabo Mahendiran; David Nanchen; David Meier; Baris Gencer; Roland Klingenberg; Lorenz Räber; David Carballo; Christian M Matter; Thomas F Lüscher; Stephan Windecker; François Mach; Nicolas Rodondi; Olivier Muller; Stephane Fournier
Journal:  J Interv Cardiol       Date:  2020-03-03       Impact factor: 2.279

8.  Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes.

Authors:  Christian Dworeck; Björn Redfors; Oskar Angerås; Inger Haraldsson; Jacob Odenstedt; Dan Ioanes; Petur Petursson; Sebastian Völz; Jonas Persson; Sasha Koul; Dimitrios Venetsanos; Anders Ulvenstam; Robin Hofmann; Jens Jensen; Per Albertsson; Truls Råmunddal; Anders Jeppsson; David Erlinge; Elmir Omerovic
Journal:  JAMA Netw Open       Date:  2020-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.